Indication: For treatment of edema when an agent with greater diuretic potential than those commonly employed is required used in pulmonary oedema in congestive cardiac failure; Renal and hepatic disease
Pharmacology: Ethacrynic acid, a monosulfonamyl diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Ethacrynic acid is used alone or with atenolol in the management of hypertension and edema.
Mechanism Of Action: Ethacrynic acid inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Ethacrynic acid indirectly increases potassium excretion via the sodium-potassium exchange mechanism.
Interactions:
DrugBank: Interactions for Ethacrynic acid
Drug Interactions for Ethacrynic acid:
Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk
of lithium toxicity. Read circulars for lithium preparations before use of such concomitant therapy.
EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin
antibiotics. Their concurrent use should be avoided.
A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a
reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.
In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic,
natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics. Therefore, when EDECRIN
and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to
determine if the desired effect of the diuretic is obtained.
Chemical IUPAC Name: 2-[2,3-dichloro-4-(2-ethylprop-2-enoyl)phenoxy]ethanoicacid
